Viridian Therapeutics, Inc.

NasdaqCM:VRDN Stock Report

Market Cap: US$1.9b

Viridian Therapeutics Valuation

Is VRDN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VRDN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

US$320.27
Fair Value
92.8% undervalued intrinsic discount
16
Number of Analysts

Below Fair Value: VRDN ($23.15) is trading below our estimate of fair value ($320.27)

Significantly Below Fair Value: VRDN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VRDN?

Key metric: As VRDN barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for VRDN. This is calculated by dividing VRDN's market cap by their current book value.
What is VRDN's PB Ratio?
PB Ratio5.8x
BookUS$326.28m
Market CapUS$1.93b

Price to Book Ratio vs Peers

How does VRDN's PB Ratio compare to its peers?

The above table shows the PB ratio for VRDN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average3.8x
IDYA IDEAYA Biosciences
2.9x14.16%US$2.8b
CDTX Cidara Therapeutics
5.2x28.37%US$2.8b
XENE Xenon Pharmaceuticals
5.1x24.01%US$3.2b
DNLI Denali Therapeutics
2.2x27.57%US$2.4b
VRDN Viridian Therapeutics
5.8x48.95%US$1.9b

Price-To-Book vs Peers: VRDN is expensive based on its Price-To-Book Ratio (5.8x) compared to the peer average (3.8x).

Price to Book Ratio vs Industry

How does VRDN's PB Ratio compare vs other companies in the US Biotechs Industry?

53 CompaniesPrice / BookEstimated GrowthMarket Cap
NKTX Nkarta
0.4x1.69%US$149.86m
ZNTL Zentalis Pharmaceuticals
0.4x13.87%US$108.20m
MGX Metagenomi
0.5x-16.66%US$95.33m
XBIT XBiotech
0.4xn/aUS$71.65m
VRDN 5.8xIndustry Avg. 2.5xNo. of Companies76PB0246810+
53 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: VRDN is expensive based on its Price-To-Book Ratio (5.8x) compared to the US Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is VRDN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VRDN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio5.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate VRDN's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VRDN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$23.15
US$38.25
+65.23%
24.78%US$61.00US$19.00n/a16
Oct ’26US$21.27
US$37.88
+78.07%
25.20%US$61.00US$19.00n/a16
Sep ’26US$18.38
US$37.88
+106.07%
25.20%US$61.00US$19.00n/a16
Aug ’26US$17.41
US$38.31
+120.06%
25.90%US$61.00US$19.00n/a16
Jul ’26US$14.47
US$38.31
+164.77%
25.90%US$61.00US$19.00n/a16
Jun ’26US$13.92
US$38.31
+175.23%
25.90%US$61.00US$19.00n/a16
May ’26US$13.74
US$39.69
+188.85%
23.95%US$61.00US$22.00n/a16
Apr ’26US$12.56
US$39.69
+215.98%
23.95%US$61.00US$22.00n/a16
Mar ’26US$15.53
US$40.00
+157.57%
23.73%US$61.00US$22.00n/a16
Feb ’26US$19.38
US$40.44
+108.66%
23.33%US$61.00US$22.00n/a16
Jan ’26US$19.17
US$40.44
+110.94%
23.33%US$61.00US$22.00n/a16
Dec ’25US$21.55
US$40.63
+88.52%
21.21%US$61.00US$22.00n/a16
Nov ’25US$22.28
US$39.25
+76.17%
21.63%US$56.00US$22.00US$23.6316
Oct ’25US$23.61
US$39.25
+66.24%
21.63%US$56.00US$22.00US$21.2716
Sep ’25US$14.68
US$35.19
+139.70%
23.25%US$46.00US$20.00US$18.3816
Aug ’25US$16.28
US$35.19
+116.14%
23.44%US$46.00US$20.00US$17.4116
Jul ’25US$13.21
US$35.19
+166.37%
23.44%US$46.00US$20.00US$14.4716
Jun ’25US$11.95
US$36.50
+205.44%
21.69%US$46.00US$20.00US$13.9214
May ’25US$13.81
US$39.36
+184.99%
12.02%US$46.00US$30.00US$13.7414
Apr ’25US$17.26
US$39.36
+128.03%
12.02%US$46.00US$30.00US$12.5614
Mar ’25US$19.89
US$38.67
+94.40%
13.58%US$46.00US$29.00US$15.5315
Feb ’25US$20.00
US$39.27
+96.33%
14.86%US$50.00US$29.00US$19.3815
Jan ’25US$21.78
US$39.33
+80.59%
14.84%US$50.00US$29.00US$19.1715
Dec ’24US$17.22
US$39.80
+131.13%
16.05%US$50.00US$29.00US$21.5515
Nov ’24US$12.60
US$41.36
+228.23%
16.54%US$57.00US$30.00US$22.2814
US$38.25
Fair Value
39.5% undervalued intrinsic discount
16
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/03 05:24
End of Day Share Price 2025/11/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Viridian Therapeutics, Inc. is covered by 28 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Kalpit PatelB. Riley Securities, Inc.
Madhu KumarB. Riley Securities, Inc.